Clinical trialNCT05722418RecruitingPhase 1Interventional

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

SponsorCaribou Biosciences, Inc.Enrollment50Relapsed/Refractory Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
Cu Anschutz Medical Campus, Anshutz Cancer Pavillion
Aurora, Colorado, United States
Daniel Sherbenou, MD, PhD
Recruiting
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
Miami, Florida, United States
Jay Spiegel, MD
Recruiting
University of Kentucky/ Markey Cancer Center
Lexington, Kentucky, United States
Gregory Monohan, MD
Recruiting
Hackensack Meridian John Theurer Cancer Center
Hackensack, New Jersey, United States
David Siegal, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Adriana Rossi, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Sham Mailankody, MBBS
Recruiting
Levine Cancer Institute
Charlotte, North Carolina, United States
Manisha Bhutani, MD
Recruiting
Duke University Health System (duhs)
Durham, North Carolina, United States
Cristina Gasparetto, MD
Recruiting
Oncology Hematology Care, Inc
Cincinnati, Ohio, United States
James Essell, MD
Recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Faiz Anwer, MD
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Jesus Berdeja, MD
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Larry Anderson, MD
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Douglas Sborov, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
William Clark, MD
Recruiting
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Binod Dhakal, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CB-011

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Feb 2023
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 25 Sept 2025
Registered enrollment: 50
Registry id: NCT05722418

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.